Patent classifications
C
CHEMISTRY; METALLURGY
Load children
C07
ORGANIC CHEMISTRY
Load children
C07C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
Load children
311/00
Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
Load children Filter patents View analytics View as hierarchy Open in page
C07C311/30
Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
Load children Filter patents View analytics View as hierarchy Open in page
C07C311/37
having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
Load children Filter patents View analytics View as hierarchy Open in page
C07C311/38
having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
Load children Filter patents View analytics View as hierarchy Open in page
C07C311/39
having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
Load children Filter patents View analytics View as hierarchy Open in page
C07C311/42
to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
Filter patents View analytics View as hierarchy Open in page

C07C311/42

Fluorescent pI markers for isoelectric focusing separations and fluorescent labeling
09689841 · 2017-06-27 · ·

UV-Absorbing and fluorescent pl markers for isoelectric focusing separations and fluorescent labeling, and methods for making and using the markers.

Fluorescent pI markers for isoelectric focusing separations and fluorescent labeling
09689841 · 2017-06-27 · ·

UV-Absorbing and fluorescent pl markers for isoelectric focusing separations and fluorescent labeling, and methods for making and using the markers.

Compounds As NLRP3 Inflammasome Inhibitors And Their Use As Medicaments
20250289810 · 2025-09-18 ·

The present invention relates to an hexahydro-s-indacene compound of Formula (I) or its pharmaceutically acceptable salt wherein A is selected from the group consisting of (A1), (A2) and (A3) as defined in the claims. The compounds of the invention are medicaments for use in the treatment of immunopathologies related to the NLRP3 inflammasome, such as for example cancer, metabolic disorders, migraine, wound repair, neurodegenerative diseases and autoimmune diseases. The hexahydro-s-indacene compound of the invention is a selective inhibitor of the activation of the NL-RP3 inflammasome and, as such, is capable of reducing the NLRP3-mediated production of interleukin-1 and interleukin 18 in mammalian cells and tissues.

##STR00001##

Compounds As NLRP3 Inflammasome Inhibitors And Their Use As Medicaments
20250289810 · 2025-09-18 ·

The present invention relates to an hexahydro-s-indacene compound of Formula (I) or its pharmaceutically acceptable salt wherein A is selected from the group consisting of (A1), (A2) and (A3) as defined in the claims. The compounds of the invention are medicaments for use in the treatment of immunopathologies related to the NLRP3 inflammasome, such as for example cancer, metabolic disorders, migraine, wound repair, neurodegenerative diseases and autoimmune diseases. The hexahydro-s-indacene compound of the invention is a selective inhibitor of the activation of the NL-RP3 inflammasome and, as such, is capable of reducing the NLRP3-mediated production of interleukin-1 and interleukin 18 in mammalian cells and tissues.

##STR00001##

Methods and compositions for targeting Tregs using CCR8 inhibitors
12552753 · 2026-02-17 · ·

The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells. ##STR00001##